We recently published a list of Jim Cramer Discusses These 13 Stocks & Rejects The AI PC Super Cycle. In this article, we are ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

When CP companies do innovate in 2025, they plan to focus on truly novel products rather than minor enhancements or changes ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

In this edition of MILS Legal Surgery, Professor Henry Blair takes a close look at three big-ticket issues that dealers ...

Johnson & Johnson is a holding company ... and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines ...

The principles of magic aren’t confined to the stage—they’re incredibly effective in the world of marketing as well.

Plus, Lodi Community Foundation lands a $30 million bequest, and the Ukrainian Catholic University Foundation gets millions ...

Innovation remains core, seen in new products such as SPRAVATO for depression and the OTTAVA robotic system. Johnson & Johnson recently concentrated on fostering innovations within its segments ...